Given the observed elevated IL-6 levels in some CIP patients, it is unsurprising that CRP levels are increased in NSCLC patients who develop CIP postatezolizumab treatment compared with baseline (92, 93). Here, CRP is linked to hereditary sensory and autonomic neuropathy.